“MGH researchers and clinicians continue to make unprecedented progress for patients as they develop novel cell and gene therapies,” said Peter L. Slavin, MD, president of the MGH.
“This collaboration with ElevateBio will enable us to amplify our efforts in the development and manufacture of cell and gene therapies.”
"At Boston Children’s Hospital, we are proud of the foundation we’ve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio— a company so well positioned to change the face of cell and gene therapy forever— is a natural fit into our overall vision,” said David Williams, MD, the hospital’s chief of hematology/oncology. “Using ElevateBio’s world-class enabling technologies, this alliance will help catalyze the science being conducted in the labs across Boston Children’s."
ElevateBio’s proven expertise in the discovery and development of new cell and gene therapies is driven by the vision of academic partners in the advancement of life-changing treatments. We offer a new approach for alliance building, and the development of new companies with the world’s leading scientific leaders, to advance their highly innovative programs quickly and efficiently.
Core to ElevateBio’s vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and translational research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners, are supported by ElevateBio. BaseCamp Academic researchers provide the vision, we provide the technology.
Meet the scientists and operators that bring decades of shared knowledge to the development of life transforming cell and gene therapies. Their knowhow moves potential product candidates from concept to commercialization.